New hepatitis b treatment trial targets silent virus carriers
NCT ID NCT05797714
Summary
This study is testing whether the drug TMF can safely control Hepatitis B virus in people who have normal liver enzyme levels. Researchers are enrolling 200 patients who have never received treatment before to see if TMF reduces virus levels and prevents liver damage. The trial compares TMF against no treatment to determine if earlier intervention helps this specific patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing You'An Hospital, Capital Medical University
Beijing, China
-
Fuyang Second People's Hospital
Fuyang, China
-
Jiangsu Province Hospital
Nanjin, China
-
LiShui People's Hospital of Zhejiang Province
Lishui, China
-
People's Hospital of Dongyang City
Dongyang, China
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai, China
-
Shanghai East Hospital
Shanghai, China
-
The Fifth People's Hospital of Suzhou
Suzhou, China
-
The Fifth People's Hospital of Wuxi
Wuxi, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province
Hangzhou, China
-
The Second Xiangya Hospital, Central South University
Changsha, Hunan, China
Conditions
Explore the condition pages connected to this study.